These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

346 related items for PubMed ID: 18475000

  • 1. Correcting Hatch-Waxman.
    Fernandes M.
    Health Aff (Millwood); 2008; 27(3):902-3; author reply 903. PubMed ID: 18475000
    [No Abstract] [Full Text] [Related]

  • 2. Congress works to permit 'biosimilar' drugs very soon.
    Carroll J.
    Manag Care; 2009 Apr; 18(4):7-8. PubMed ID: 19472559
    [No Abstract] [Full Text] [Related]

  • 3. The Hatch-Waxman Act: balancing competing interests or survival of the fittest?
    Behrendt KE.
    Food Drug Law J; 2002 Apr; 57(2):247-71. PubMed ID: 12436990
    [No Abstract] [Full Text] [Related]

  • 4. The ongoing regulation of generic drugs.
    Frank RG.
    N Engl J Med; 2007 Nov 15; 357(20):1993-6. PubMed ID: 18003956
    [No Abstract] [Full Text] [Related]

  • 5. Branded drug reformulation: the next brand vs. generic antitrust battleground.
    Amoresano GV.
    Food Drug Law J; 2007 Nov 15; 62(1):249-56. PubMed ID: 17444032
    [No Abstract] [Full Text] [Related]

  • 6. Using a drug-safety tool to prevent competition.
    Sarpatwari A, Avorn J, Kesselheim AS.
    N Engl J Med; 2014 Apr 17; 370(16):1476-8. PubMed ID: 24738666
    [No Abstract] [Full Text] [Related]

  • 7. Old drugs, new uses: solving a Hatch-Waxman patent predicament.
    McPhie DC.
    Food Drug Law J; 2004 Apr 17; 59(1):155-68. PubMed ID: 15190929
    [No Abstract] [Full Text] [Related]

  • 8. Striking the right balance between innovation and drug price competition: understanding the Hatch-Waxman Act--an introduction of speakers.
    Rea TS.
    Food Drug Law J; 1999 Apr 17; 54(2):223-5. PubMed ID: 11759713
    [No Abstract] [Full Text] [Related]

  • 9. Is Noerr-Pennington immunity still a viable defense against antitrust claims arising from Hatch-Waxman litigation?
    Steinhauer EH.
    Food Drug Law J; 2006 Apr 17; 61(4):679-700. PubMed ID: 17180769
    [No Abstract] [Full Text] [Related]

  • 10. Path to approval proves rocky for copycat biodrugs.
    Wadman M.
    Nature; 2005 Nov 10; 438(7065):154-5. PubMed ID: 16281004
    [No Abstract] [Full Text] [Related]

  • 11. Drug marketing exclusivity under United States and European Union law.
    Junod V.
    Food Drug Law J; 2004 Nov 10; 59(4):479-518. PubMed ID: 15875347
    [No Abstract] [Full Text] [Related]

  • 12. The response to health care reform by the pharmaceutical industry.
    Krulwich AS.
    Food Drug Law J; 1995 Nov 10; 50(1):1-22. PubMed ID: 10342983
    [No Abstract] [Full Text] [Related]

  • 13. [European drug policy: welcomed modernization but shortage of political proposals concerning industry and research].
    Alván G.
    Lakartidningen; 2003 Oct 30; 100(44):3541-2. PubMed ID: 14651017
    [No Abstract] [Full Text] [Related]

  • 14. Generic drugs: the stalling game.
    Consum Rep; 2001 Jul 30; 66(7):36-40. PubMed ID: 11725791
    [Abstract] [Full Text] [Related]

  • 15. A generic problem.
    Hanauer SB.
    Nat Clin Pract Gastroenterol Hepatol; 2006 Dec 30; 3(12):649. PubMed ID: 17130869
    [No Abstract] [Full Text] [Related]

  • 16. A Citizen's Pathway Gone Astray - Delaying Competition from Generic Drugs.
    Feldman R, Wang C.
    N Engl J Med; 2017 Apr 20; 376(16):1499-1501. PubMed ID: 28248550
    [No Abstract] [Full Text] [Related]

  • 17. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma.
    Wang Z.
    Cornell Law Rev; 2014 Jul 20; 99(5):1227-58. PubMed ID: 25112001
    [No Abstract] [Full Text] [Related]

  • 18. The Drug Price Competition and Patent Term Restoration Act of 1984: fine-tuning the balance between the interests of pioneer and generic drug manufacturers.
    Soehnge H.
    Food Drug Law J; 2003 Jul 20; 58(1):51-80. PubMed ID: 12739584
    [No Abstract] [Full Text] [Related]

  • 19. Antibiotics--an investment worth making?
    Christoffersen RE.
    Nat Biotechnol; 2006 Dec 20; 24(12):1512-4. PubMed ID: 17160052
    [Abstract] [Full Text] [Related]

  • 20. Delaying generic competition--corporate payoffs and the future of Plavix.
    Shuchman M.
    N Engl J Med; 2006 Sep 28; 355(13):1297-300. PubMed ID: 17005945
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.